The Annual General Meeting of Devyser Diagnostics AB (publ) (“Devyser” or the “Company”) was held on Wednesday, 6 May 2026 at Bränningevägen 12, 120 54 Årsta. The main resolutions passed…
“Devyser is reporting its fourth consecutive quarter with a positive operating result. This is an outcome we are delivering in an external environment that continues to present…
On Monday April 27 at 11:00 a.m. CET, Devyser Diagnostics AB will host an online presentation of its Q1 2026 report (which will have been published earlier on April 27 at 09:00 a.m.…
Devyser Diagnostics AB today announces that the company’s Chief Commercial Officer (CCO), Theis Kipling, has decided to leave Devyser to take up a position with another company.
“During…
Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, announces that the acquisition of all shares in CyberGene AB (“CyberGene”) that was announced on 11 February 2026…
Devyser´s annual report 2025 has today been published on the company´s website.The report is available on: https://investors.devyser.com/en/reports-presentationsThe financial year covers…
Devyser, today announced the launch of Devyser Thalassemia v2, the first Next-Generation Sequencing (NGS) assay for genetic analysis of thalassemia and sickle cell disease (SCD) available…
“The fourth quarter confirmed the positive earnings trend that we have seen throughout the year. Operating profit amounted to SEK 18.0 million (-3.7) for the quarter and to SEK 10.1…
Devyser Diagnostics AB (publ), a Swedish molecular diagnostics company, today announces that it has entered into an agreement relating to the acquisition of 100 percent of the shares in…
On Thursday February 12 at 9:00 a.m. CET, Devyser Diagnostics AB will host an online presentation of its Q4 2025 report (which will have been published earlier on February 12 at 07:30…
